XEOMIN Dosing Recommendations for Blepharospasm

 

Click here to download the muscle injection tracker.

  • The potency units for XEOMIN® (incobotulinumtoxinA) are specific to the preparation and not interchangeable with other botulinum toxin A products
  • Response to XEOMIN and onabotulinumtoxinA (Botox®) may differ in individual patients
  • Dosing of XEOMIN has not been established in patients with blepharospasm who have not been treated previously with onabotulinumtoxinA (Botox)
  • The safety and effectiveness of XEOMIN in the treatment of blepharospasm in patients <18 years of age have not been assessed

hcp_3.3_dosing_bleph_table

*The maximum dose per eye in the clinical trial was 50 units, with a range of 10–50 units. Few patients received a total dose greater than 75 units.1

Available in 50-, 100-, 200-unit single-use vials1

50-unit vial may allow for more precise billing and may help reduce wastage.

Dosing recommendations for adults with blepharospasm

The recommended initial total dose of XEOMIN should be the same dose as the patient’s previous treatment of onabotulinumtoxinA, although responses to XEOMIN and onabotulinumtoxinA may differ in individual patients.1

In a placebo-controlled trial where patients were dosed with the same number of units as they had received previously with onabotulinumtoxinA, the mean dose per eye was about 33 units (range 10–50 units), and the mean number of injections per eye was 6. The maximum dose per eye in the controlled trials was 50 units, with a range of 10–50 units. In the controlled trial, few patients received a total dose of greater than 75 units.1

If the previous dose of onabotulinumtoxinA is not known, the initial dose of XEOMIN should be 1.25–2.5 units/injection site. The total initial dose of XEOMIN in both eyes should not exceed 70 units (35 units/eye). The number and location of injection sites should be based on the severity of blepharospasm and previous dose and response to onabotulinumtoxinA injections. Subsequent dosing should be tailored to the individual patient, based on response, up to a maximum dose of 35 units per eye. XEOMIN dosing has not been established in patients with blepharospasm who have not been previously treated with onabotulinumtoxinA. The frequency of XEOMIN repeat treatments should be determined by clinical response but should generally be no more frequent than every 12 weeks.1

hcp_3.3_median_dose_bleph

Reference

  1. XEOMIN® [package insert]. Raleigh, NC: Merz North America, Inc; 2015.